- Home
- ANAB vs CHY Comparison
ANAB vs CHY Comparison
Compare ANAB & CHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- CHY
- Stock Information
- Founded
- ANAB 2005
- CHY 2003
- Country
- ANAB United States
- CHY United States
- Employees
- ANAB N/A
- CHY N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- CHY Investment Managers
- Sector
- ANAB Health Care
- CHY Finance
- Exchange
- ANAB Nasdaq
- CHY Nasdaq
- Market Cap
- ANAB 759.5M
- CHY 760.9M
- IPO Year
- ANAB 2017
- CHY N/A
- Fundamental
- Price
- ANAB $19.59
- CHY $10.36
- Analyst Decision
- ANAB Buy
- CHY
- Analyst Count
- ANAB 10
- CHY 0
- Target Price
- ANAB $37.75
- CHY N/A
- AVG Volume (30 Days)
- ANAB 589.1K
- CHY 128.3K
- Earning Date
- ANAB 05-05-2025
- CHY 01-01-0001
- Dividend Yield
- ANAB N/A
- CHY 10.11%
- EPS Growth
- ANAB N/A
- CHY N/A
- EPS
- ANAB N/A
- CHY N/A
- Revenue
- ANAB $111,872,000.00
- CHY N/A
- Revenue This Year
- ANAB N/A
- CHY N/A
- Revenue Next Year
- ANAB $44.69
- CHY N/A
- P/E Ratio
- ANAB N/A
- CHY N/A
- Revenue Growth
- ANAB 387.20
- CHY N/A
- 52 Week Low
- ANAB $12.21
- CHY $9.97
- 52 Week High
- ANAB $41.31
- CHY $12.16
- Technical
- Relative Strength Index (RSI)
- ANAB 48.98
- CHY 59.10
- Support Level
- ANAB $18.51
- CHY $10.10
- Resistance Level
- ANAB $21.52
- CHY $10.26
- Average True Range (ATR)
- ANAB 1.16
- CHY 0.12
- MACD
- ANAB -0.26
- CHY 0.05
- Stochastic Oscillator
- ANAB 26.97
- CHY 100.00
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.